In summary, our experiments suggest that TRIM9 plays an oncogenic role in bladder cancer progression by increasing cell proliferation, migration, and inducing chemoresistance via CEACAM6/Smad2/3 signaling pathway. This evidence concerns the gene SMAD2 and urinary bladder cancer.